EP1007048A4 - Identifizierung von mitteln zur behandlung der alzheimerischen krankheit - Google Patents

Identifizierung von mitteln zur behandlung der alzheimerischen krankheit

Info

Publication number
EP1007048A4
EP1007048A4 EP98911551A EP98911551A EP1007048A4 EP 1007048 A4 EP1007048 A4 EP 1007048A4 EP 98911551 A EP98911551 A EP 98911551A EP 98911551 A EP98911551 A EP 98911551A EP 1007048 A4 EP1007048 A4 EP 1007048A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
identification
treatment
agents useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98911551A
Other languages
English (en)
French (fr)
Other versions
EP1007048A1 (de
Inventor
Ashley I Bush
Xudong Huang
Craig S Atwood
Rudolph E Tanzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1007048A1 publication Critical patent/EP1007048A1/de
Publication of EP1007048A4 publication Critical patent/EP1007048A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
EP98911551A 1997-03-11 1998-03-11 Identifizierung von mitteln zur behandlung der alzheimerischen krankheit Withdrawn EP1007048A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81612297A 1997-03-11 1997-03-11
US816122 1997-03-11
PCT/US1998/004683 WO1998040071A1 (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1007048A1 EP1007048A1 (de) 2000-06-14
EP1007048A4 true EP1007048A4 (de) 2004-09-22

Family

ID=25219748

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98911551A Withdrawn EP1007048A4 (de) 1997-03-11 1998-03-11 Identifizierung von mitteln zur behandlung der alzheimerischen krankheit

Country Status (5)

Country Link
EP (1) EP1007048A4 (de)
JP (1) JP2001514661A (de)
AU (1) AU748768B2 (de)
CA (1) CA2284170C (de)
WO (1) WO1998040071A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
IL134263A (en) 1997-08-21 2006-04-10 Gerolymatos P N Sa Pharmaceutical compositions containing phanquinone for the treatment of alzheimer's disease
JP2001519529A (ja) 1997-10-06 2001-10-23 ザ ジェネラル ホスピタル コーポレイション 遅発性ジスキネジーを予測するために薬物をスクリーニングするための方法
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
AU1792200A (en) 1999-01-07 2000-07-24 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
ATE283285T1 (de) * 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
EP1266884A4 (de) * 2000-03-22 2003-04-23 Bf Res Inst Inc Sonde zur bilddiagnose, basiert auf substituiertes azobenzol oder seine analoga, für krankheiten welche der amyloidakkumulation zugeschrieben werden, und dieses enthaltende gemische zur bilddiagnose
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
AU2002351880B2 (en) * 2001-12-27 2007-08-30 Neuroscientific Biopharmaceuticals Pty Ltd Screening methods and the use of agents identified using the same
EP2500018B1 (de) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Verhindern und/oder Behandeln der kardiovaskulären Erkrankung und/oder zugehöriges Herzversagen
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
EP1606292A2 (de) * 2003-03-21 2005-12-21 Palumed SA Stickstoffhaltige polyzyklische derivate verwendbar als chelatoren von metall ionen und ihre anwendung
CN102293746A (zh) * 2003-09-09 2011-12-28 吉里德科学公司 治疗性脂质体
CA2550505A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1778618B1 (de) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthese von triethylenetetraminen
ES2473587T3 (es) 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
WO2009108999A1 (en) 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
WO2018236221A2 (en) * 2017-06-03 2018-12-27 Can Holding B.V. Neurodegenerative peptide deposit dissolution
KR102048846B1 (ko) * 2017-11-20 2019-11-27 한국생명공학연구원 혈관 질환 치료제 및 이의 스크리닝 방법
JP7618230B2 (ja) * 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681844A1 (de) * 1993-11-30 1995-11-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substanz zum ermitteln von amyloidablagerungen
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
DE69227380T3 (de) * 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681844A1 (de) * 1993-11-30 1995-11-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substanz zum ermitteln von amyloidablagerungen
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BACON ET AL: "Rheumatoid Diesease, Amyloidosis and its Treatment with Penicillamine", EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION, CAMERON PUBLISHERS, CASTLETOWN, GB, vol. 3, no. 2, 1979, pages 70 - 74, XP002117959, ISSN: 0104-1610 *
See also references of WO9840071A1 *

Also Published As

Publication number Publication date
EP1007048A1 (de) 2000-06-14
CA2284170A1 (en) 1998-09-17
AU6548498A (en) 1998-09-29
JP2001514661A (ja) 2001-09-11
WO1998040071A1 (en) 1998-09-17
CA2284170C (en) 2008-12-02
AU748768B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
EP0963219A4 (de) Bearbeitung von nitrosativen und oxidativen stress zur behandlung einer krankheit
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
FI964284A7 (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
EP1043991A4 (de) Behandlung der alzheimer-erkrankung
EP0988265A4 (de) Behandlung von schweren aromaten
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
PL348226A1 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
DE69604228D1 (de) Pupillen Messanordnung und Alzheimer Krankheits Diagnosesystem
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
EP0760659A4 (de) Applikation von alpha-hydroxy-säuren zur behandlung von striae distensae
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
DE69825888D1 (de) Diagnostisches verfahren der alzheimer-erkrankung
EP1030680A4 (de) Behandlung von kaposisarkom mit il-12
EP0866799A4 (de) Apolipoprotein e2 und behandlung der alzheimerschen krankheit
FR2774596B1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
EP1173189A4 (de) Asialozytokine und behandlung von leber erkrankungen
EP0840605A4 (de) Verbindungen zur verwendung in der behandlung von neurofibromatose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 01N 59/08 B

Ipc: 7A 01N 43/60 B

Ipc: 7A 01N 43/40 B

Ipc: 7A 01N 43/38 B

Ipc: 7A 01N 43/32 B

Ipc: 7A 01N 43/00 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 01N 37/12 B

Ipc: 7A 61K 49/00 B

Ipc: 7A 61K 38/17 B

Ipc: 7A 61K 31/545 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040811

17Q First examination report despatched

Effective date: 20050421

17Q First examination report despatched

Effective date: 20050421

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20081212BHEP

Ipc: A61K 38/17 20060101ALI20081212BHEP

Ipc: A61K 31/545 20060101AFI20081212BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090721